Evolving therapies in neuronopathic LSDs: opportunities and challenges.

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Lysosomal storage disorders (LSDs) are a group of rare, inherited metabolic diseases caused by genetic defects affecting lysosomal enzymes.
• These multisystemic disorders often lead to progressive cellular damage and can manifest with severe neurological symptoms.
• The true prevalence of LSDs may be underestimated, particularly those with significant neurological involvement.

Purpose of the Study:

• To review current therapeutic approaches for neuronopathic lysosomal storage disorders (nLSDs).
• To explore ongoing clinical trials targeting neurological manifestations in nLSDs.
• To identify emerging opportunities and persistent challenges in treating nLSDs.

Main Methods:

• Literature review of current therapeutic strategies for nLSDs.
• Analysis of ongoing clinical trials for nLSDs.
• Synthesis of information on treatment outcomes and challenges.

Main Results:

• A significant proportion of LSDs (over two-thirds) involve neurodegeneration.
• Neurological phenotype is a critical determinant of disease progression and treatment efficacy in nLSDs.
• Various therapeutic strategies are under investigation, including enzyme replacement therapy, substrate reduction therapy, and gene therapy.

Conclusions:

• Neurological involvement in LSDs presents a major therapeutic hurdle.
• Advances in understanding nLSDs offer new avenues for treatment development.
• Continued research and clinical trials are crucial for improving patient outcomes in nLSDs.